Key facts
- CereVasc’s last known valuation is $135.0M.
- It has raised $113.9M across 1 recorded rounds; the latest was Early Stage VC ($11.1M) in May 2020.
- Notable investors include Perceptive Advisors, Bain Capital Life Sciences, ATON Partners, Tufts Medical Center, Xontogeny.
- CereVasc has filed 1 Form D with the SEC, most recently Jun 2020 ($11.1M sold to 5 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for CereVasc
Funding rounds
1 roundsAbout CereVasc
Operator of a medical device company intended to treat patients with neurological diseases. The company's products comprise an endovascularly implantable CSF shunt and associated delivery componentry designed to avoid the need for invasive surgery, general anesthesia, extended hospitalization, and post-procedure pain management, enabling doctors to treat various neurological brain disorders efficiently with minimally invasive treatments.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2014
- Employees
- 32
- Website
- cerevasc.com/
- Ownership
- Privately Held (backing)
CereVasc doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in CereVasc shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on CereVasc in its N-PORT filings yet. We sweep new filings monthly.